InMed Pharmaceuticals Inc. (MTRI) revenue by segment
MTRINasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as INM
$17.50−2.37 (-11.93%)
Close on Nov 17, 2026Market cap $96.14MP/E –Yield –
InMed Pharmaceuticals Inc. revenue by segment
Periods
By business segment
| Operating income | FY2026CY2026 | FY2025CY2025 | FY2024CY2024 | FY2023CY2023 | FY2022CY2022 | YoY |
|---|---|---|---|---|---|---|
| BayMedica | – | – | – | -$1.21M | -$5.19M | – |
| InMed | – | – | – | -$6.74M | -$13.41M | – |
By product or service
By region
From the segment and revenue-disaggregation notes of InMed Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes. The KPIs tab shows these segments next to InMed Pharmaceuticals's operating metrics, with full history, charts and a link to each filing.
See a number that looks wrong?